These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

695 related items for PubMed ID: 25968903

  • 1. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA, Smith-Gagen JA.
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 4. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 5. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.
    Asian Pac J Cancer Prev; 2015 Sep; 16(12):5013-8. PubMed ID: 26163633
    [Abstract] [Full Text] [Related]

  • 6. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T, Thiele J, Vannucchi AM, Tefferi A.
    Blood Cancer J; 2015 Aug 14; 5(8):e337. PubMed ID: 26832847
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct 14; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 9. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
    Macedo LC, de Cesare Quintero F, Pagliari-E-Silva S, Pagnano KB, Rodrigues C, de Alencar JB, Sell AM, Visentainer JE.
    Blood Cells Mol Dis; 2016 Mar 14; 57():54-7. PubMed ID: 26852656
    [Abstract] [Full Text] [Related]

  • 10. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Mar 14; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 11. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
    Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, Grabowska B, Zduńczyk A, Okoń K, Stachura J.
    Int J Hematol; 2007 Aug 14; 86(2):130-6. PubMed ID: 17875526
    [Abstract] [Full Text] [Related]

  • 12. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.
    Asian Pac J Cancer Prev; 2016 Aug 14; 17(3):923-6. PubMed ID: 27039813
    [Abstract] [Full Text] [Related]

  • 13. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
    Shallis RM, Zeidan AM, Wang R, Podoltsev NA.
    Hematol Oncol Clin North Am; 2021 Apr 14; 35(2):177-189. PubMed ID: 33641862
    [Abstract] [Full Text] [Related]

  • 14. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
    Valladares X, Benavente R, Rojas C, Peña C, Valenzuela R, Monardes V, López H, Abarca M, León P, Osorio R, Pérez E, Soto P, Rocca G, Cardemil D, Torres V, Intriago M, Cabrera ME, Undurraga MS.
    Rev Med Chil; 2021 Nov 06; 149(11):1532-1538. PubMed ID: 35735314
    [Abstract] [Full Text] [Related]

  • 17. Thrombosis among 1537 patients with JAK2V617F -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model.
    Zhang Y, Zhou Y, Wang Y, Teng G, Li D, Wang Y, Du C, Chen Y, Zhang H, Li Y, Fu L, Chen K, Bai J.
    Cancer Med; 2020 Mar 06; 9(6):2096-2105. PubMed ID: 31994332
    [Abstract] [Full Text] [Related]

  • 18. JAK2 p.(V617F) mutation in Tunisian myeloproliferative neoplasms and its genotype-phenotype correlation.
    Sassi H, Menif S, Ammar SB, Farrah A, Othmen HBH, Amouri H.
    Pan Afr Med J; 2021 Mar 06; 39():194. PubMed ID: 34603575
    [Abstract] [Full Text] [Related]

  • 19. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E, Passamonti F, Rumi E, Pietra D, Elena C, Arcaini L, Pascutto C, Castello A, Cazzola M, Magrini U, Lazzarino M.
    Br J Haematol; 2008 Jan 06; 140(2):162-8. PubMed ID: 18028479
    [Abstract] [Full Text] [Related]

  • 20. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, Nomura K, Nakamura T, Morishige S, Oku E, Osaki K, Hashiguchi E, Mouri F, Yoshimoto K, Nagafuji K, Okamura T.
    Kurume Med J; 2014 Jan 06; 60(3-4):89-97. PubMed ID: 24858412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.